Primarily nuclear imaging techniques such as single-photon emission computed tomography (SPECT), positron emission tomography (PET), and bone scintigraphy are taken along with other data before a patient is diagnosed for Condylar Hyperplasia. In SPECT imaging, an increase uptake of the isotope is seen on the affected in comparison to the non-affected side. A difference of at least 10% or a minimum ratio of 55% to 45% uptake of technetium-99m is seen when comparing affected vs non-affected side respectively. An uptake of more than 55% and difference of at least 10% indicates an active condylar growth. Classification
Hugo Obwegesr and Makek classified condylar hyperplasia into three categories, listed in the table below. Type 1 develops its characteristics from the horizontal vector, and Type 2 develops its characteristics from the vertical vector. Type 1 CH occurs much more common (15x) than Type 2 CH. Wolford et al. in 2014, developed an updated classification of condylar hyperplasia. In 1986, Slootweg & Muller devised a histopathological classification which allows the condylar tissues to be classified into specific categories. Treatment
Many treatment options exist for this type of condition. Orthognathic surgery can be performed once the active condylar growth has finished in some cases. The point of this surgery to wait as long as the condyle is growing and only do surgery when the condyle stops growing, so the chances of any worsening of facial asymmetry lessens. This option, however, does include a person living with the facial asymmetry features all the way up until 18 to 19 years of age.
Side effects
Sedation is very common, and extrapyramidal side effects are common and include restlessness, dystonic reactions, pseudoparkinsonism, and akathisia; the extrapyramidal symptoms can affect 2% of people at low doses, whereas higher doses may affect as many as 40% of people.Prochlorperazine can also cause a life-threatening condition called neuroleptic malignant syndrome (NMS). Some symptoms of NMS include high fever, stiff muscles, neck muscle spasm, confusion, irregular pulse or blood pressure, fast heart rate (tachycardia), sweating, abnormal heart rhythms (arrhythmias). Research from the Veterans Administration and United States Food and Drug Administration show injection site reactions. Adverse effects are similar in children. Warning
The FDA approved label for prochlorperazine includes a warning for increased risk of mortality in elderly patients with dementia related psychosis. Discontinuation
The British National Formulary recommends a gradual withdrawal when discontinuing antipsychotics to avoid acute withdrawal syndrome or rapid relapse. Symptoms of withdrawal commonly include nausea, vomiting, and loss of appetite. Other symptoms may include restlessness, increased sweating, and trouble sleeping. Less commonly there may be a feeling of the world spinning, numbness, or muscle pains. Symptoms generally resolve after a short period of time.There is tentative evidence that discontinuation of antipsychotics can result in psychosis. It may also result in reoccurrence of the condition that is being treated. Rarely tardive dyskinesia can occur when the medication is stopped. Pharmacology
Prochlorperazine is thought to exert its antipsychotic effects by blocking dopamine receptors.Prochlorperazine is analogous to chlorpromazine; both of these agents antagonize dopaminergic D2 receptors in various pathways of the central nervous system.